Skip to main content
Canna~Fangled Abstracts

Women’s perceptions and experiences with cannabis use in menopause: a qualitative study

By July 9, 2024July 10th, 2024No Comments

. 2024 Jul 9.

doi: 10.1097/GME.0000000000002388.

Online ahead of print.
Katherine Babyn 1, Maira Quintanilha 2, Sue Ross 3, Mark Makowsky 1, Tony Kiang 1, Nese Yuksel 1
Affiliations 

Abstract

Objectives: Since the legalization of recreational cannabis in 2018, the use of cannabis for medical reasons has increased in Canada. The aim of this study was to explore the experiences and perceptions of midlife women using cannabis for medical purposes coinciding with menopause symptom management.

Methods: Semistructured, one-on-one interviews were conducted using a qualitative description method. This was the second phase of a mixed methods study, where interviewees were purposefully selected from a sample of women (ages 35 and over, located in Alberta) surveyed during the first phase of the study. Interviews were by phone or virtual meeting, audio-recorded, and transcribed verbatim. Qualitative content analysis was applied to analyze the data collected.

Results: Twelve interviews were conducted between December 2020 and April 2021. Menopause was perceived as a complex experience for women. Cannabis was described as a therapeutic agent, providing symptom relief through the menopause transition. Women reported similarities in their menopause and cannabis use experiences in the lack of information available, limited role of healthcare providers, feelings of stigmatization, and emphasis on self-education. Women self-managed their cannabis use, learning from their own experiences or the anecdotal sharing of others’, accessed cannabis from a variety of medical and nonmedical sources, and relied on experimentation, and a range of supports were described.

Conclusion: Midlife women pursued the use of cannabis medically to manage symptoms that overlap with menopause. Understanding how and why midlife women use cannabis medically can provide insight for future research and the development of educational resources to support women in menopause.

PubMed Disclaimer

Conflict of interest statement

Financial disclosure/conflicts of interest: M. Quintanilha owns Quali Q Inc and provided support for data analysis related to this work. N. Yuksel has been on the advisory boards and/or a speaker for BioSyent, Bayer, Astellas, Organon, Eisai, and Duchesnay and a recipient of an unrestricted research grant from Bayer. The other authors have nothing to disclose.

References

    1. Minkin MJ. Menopause: hormones, lifestyle, and optimizing aging. Obstet Gynecol Clin North Am 2019;46:501–514. doi: 10.1016/j.ogc.2019.04.008 – DOI
    1. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015;175:531–539. doi: 10.1001/jamainternmed.2014.8063 – DOI
    1. El Khoudary SR, Greendale G, Crawford SL, et al. The menopause transition and women’s health at midlife: a progress report from the Study of Women’s Health Across the Nation (SWAN). Menopause 2019;26:1213–1227. doi: 10.1097/gme.0000000000001424 – DOI
    1. Yuksel N, Evaniuk D, Huang L, et al. Guideline no. 422a: menopause: vasomotor symptoms, prescription therapeutic agents, complementary and alternative medicine, nutrition, and lifestyle. J Obstet Gynaecol Can 2021;43:1188–1204.e1. doi: 10.1016/j.jogc.2021.08.003 – DOI
    1. The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022;29:767–794. doi: 10.1097/GME.0000000000002028 – DOI

Leave a Reply